€ 230.5
Key Takeaways
Risk factor
Low price volatility
Profitability factor
Greatly overvalued vs peers
About
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact,...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, overvalued on P/FC.
Target Price
The average target price of TUB.BR is 220 and suggests 5% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to dec
